M&A / Deals Roche doubles down on BTK with $2.3bn Nurix deal PharmaphorumRoche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology. Hematology Read full story Post navigation Previous: Lilly and Novo face off at ADA 2026 as others seek to compete in obesityNext: Incyte gobbles up Star’s Vega haematology unit in $2bn deal Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026